Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

Mauricette Michallet*, Peter Dreger, Mohamad Sobh, Linda Koster, Jennifer Hoek, Ariane Boumendil, Christof Scheid, Christopher P Fox, Gerald Wulf, William Krüger, Michel van Gelder, Paolo Corradini, Domenico Russo, Jakob Passweg, Hélène Schoemans, Wolfgang Bethge, Nicolaas Schaap, Jan Cornelissen, Paul Browne, Nadira DurakovicLutz Muller, Silvia Montoto, Nicolaus Kroger, Johannes Schetelig, French Cooperative Group for CLL, SFGM-TC, and the EBMT Chronic Malignancy and Lymphoma Working Parties

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Keyphrases

INIS

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology